1.3 C
New York
Tuesday, January 31, 2023

Taking On Challenges And Growing? – Checkpoint Therapeutics Inc. (CKPT)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Checkpoint Therapeutics Inc. (CKPT) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.20, or 2.63%, to $7.80. The Checkpoint Therapeutics Inc. has recorded 1,001 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $7.60 and fluctuated between $8.15 as its day high and $7.28 as its day low. The current market capitalization of Checkpoint Therapeutics Inc. is $71.90M. A total of 0.28 million shares were traded on the day, compared to an average of 105.71K shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, CKPT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 8 BUYs and 12 SELLs from insiders. Insiders purchased 877,714 shares during that period but sold 765,666.

In the most recent transaction, Oliviero James F III sold 3,817 shares of CKPT for 6.75 per share on Jan 10. After the transaction, the CEO, President and Director now owns 192,382 company shares. In a previous transaction on Jan 10, GRAY WILLIAM GARRETT sold 1,858 shares at 6.75 per share. CKPT shares that Chief Financial Officer owns now total 52,533.

Among the insiders who sold shares, Oliviero James F III disposed of 15,000 shares on Jun 23 at a per-share price of $1.11. This resulted in the CEO, President and Director holding 2,562,003 shares of CKPT after the transaction. In another insider transaction, Oliviero James F III sold 12,000 shares at $1.09 per share on Jun 22. Company shares held by the CEO, President and Director now total 2,577,003.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CKPT in the last 3 months, the mean price target is $48.60 with high estimates of $96.00 and low estimates of $15.00. In terms of 52-week highs and lows, CKPT has a high of $28.20 and a low of $3.56.

As of this writing, CKPT has an earnings estimate of -$0.15 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.13 per share and a lower estimate of -$0.16. The company reported an EPS of -$0.2 in the last quarter, which was -42.90% lower than expectations of -$0.14.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CKPT is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles